Beyond Air, Inc. (XAIR): Price and Financial Metrics


Beyond Air, Inc. (XAIR): $5.13

-0.21 (-3.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

XAIR POWR Grades


  • Momentum is the dimension where XAIR ranks best; there it ranks ahead of 49.3% of US stocks.
  • The strongest trend for XAIR is in Growth, which has been heading down over the past 31 weeks.
  • XAIR ranks lowest in Quality; there it ranks in the 7th percentile.

XAIR Stock Summary

  • Beyond Air Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 9.82% of US listed stocks.
  • Beyond Air Inc's stock had its IPO on May 8, 2019, making it an older stock than only 4.08% of US equities in our set.
  • XAIR's price/sales ratio is 135.19; that's higher than the P/S ratio of 97.01% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Beyond Air Inc are CUE, ACRS, FGEN, APTX, and MDGS.
  • XAIR's SEC filings can be seen here. And to visit Beyond Air Inc's official web site, go to www.beyondair.net.

XAIR Price Target

For more insight on analysts targets of XAIR, see our XAIR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.3 (Strong Buy)

XAIR Stock Price Chart Interactive Chart >

Price chart for XAIR

XAIR Price/Volume Stats

Current price $5.13 52-week high $7.96
Prev. close $5.34 52-week low $4.62
Day low $5.11 Volume 243,800
Day high $5.36 Avg. volume 369,965
50-day MA $5.28 Dividend yield N/A
200-day MA $5.59 Market Cap 112.35M

Beyond Air, Inc. (XAIR) Company Bio


Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.


XAIR Latest News Stream


Event/Time News Detail
Loading, please wait...

XAIR Latest Social Stream


Loading social stream, please wait...

View Full XAIR Social Stream

Latest XAIR News From Around the Web

Below are the latest news stories about Beyond Air Inc that investors may wish to consider to help them evaluate XAIR as an investment opportunity.

Thursday’s Pre-Market: Here’s What You Need to Know Before the Market Opens

U.S. stock futures were mixed on Thursday as investors await data related to consumer prices. That data will provide information about the rate of inflation as the economy recovers from the pandemic. Notably, data on initial jobless claims for the recent week is also set to be released today. S&P futures were relatively flat, while Dow futures were trading around 0.2% higher, at the time of writing. Meanwhile, Nasdaq futures were trading around 0.2% lower, at the time of writing. Companies that are expected to report earnings before the market opens include AstroNova (ALOT), BlueCity Holdings (BLCT), and Signet Jewelers Limited (SIG).

Priti Ramgarhia on TipRanks | June 10, 2021

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021

Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial launch in the fourth quarter of calendar year 2021 Expanded the commercial and business development teams by appointing executives with extensive nitric oxide (NO) experience Presented positive data for 150 – 160 ppm NO from LungFit® PRO programs in hospitalized patients (adults and infants) with vi

Yahoo | June 10, 2021

Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH

GARDEN CITY, N.Y., May 26, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced an agreement with former LungFit® PH commercial licensee, Circassia Group plc. Under the terms of the agreement, Beyond Air retains United States and China commercialization rights to LungFit® PH in exchange for returning upfront and milestone payments received by the Company in 2019, along with capped future royalty payments. Beyond Air now holds full global rights to LungFit® PH. Beyond Air will repay Ci...

Yahoo | May 26, 2021

Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast

Call scheduled for Thursday, June 10th at 4:30 pm Eastern TimeGARDEN CITY, N.Y., May 25, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its fourth fiscal quarter and year ended March 31, 2021 on Thursday, June 10, 2021. The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. Conference Call & WebcastThursday, June 10, 2021, 4:30 PM ETDomestic:877-407-0784International:201-689...

Yahoo | May 25, 2021

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021

Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit® PRO is well-tolerated with no treatment-related adverse events, and demonstrates encouraging efficacy signals Further analysis of 3 previously reported pilot studies in bronchiolitis at 150-160 ppm NO demonstrates a favorable safety profile and consistent efficacy across multiple endpoints Entirety of data at 150-160 ppm NO in both adult and infant patient populations supports further development of LungFit® PRO in patients hospitalized with viral pneumonia GARDEN CITY, N.Y., May 13, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on devel...

Yahoo | May 13, 2021

Read More 'XAIR' Stories Here

XAIR Price Returns

1-mo -0.19%
3-mo -9.20%
6-mo -1.16%
1-year -31.42%
3-year 65.48%
5-year N/A
YTD -2.66%
2020 0.76%
2019 12.47%
2018 -6.81%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7387 seconds.